Medesthetics

MAR-APR 2013

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link: https://medesthetics.epubxp.com/i/111786

Contents of this Issue

Navigation

Page 44 of 90

ANTIAGING SKIN CARE studied and most promising agent for doing that is Retin A. It is the one substance with molecules small enough to penetrate the epidermis and reach skin receptors to stimulate the natural production of collagen and elastin. Retinol in high enough concentration with the right delivery system has been shown to reduce the signs of aging.��� ���It is the one substance with molecules small enough to penetrate the epidermis and reach skin receptors.��� In March 2012, Dr. Obagi introduced ZO Medical, a line of 11 products available exclusively through physicians. ZO Medical includes two cleansers, a toner, Cebatrol to help control acne, Brightenex with a blend of 1% retinol and melanin inhibitors for skin discoloration, Glycogent to help reduce in���ammation, Retamax with retinol for antiaging, and four prescription-only products containing hydroquinone or tretinoin. In January 2012, Elizabeth Ho and colleagues published results of a clinical trial comparing nonprescription 40 MARCH/APRIL 2013 | MedEsthetics tri-retinol 1.1% gradual release cream and prescriptiononly tretinoin 0.025% cream in a randomized, doubleblind, controlled study of 34 subjects. They concluded that there were no signi���cant differences in ef���cacy between the two groups (16 used tri-retinol and 18 used tretinoin), and both products signi���cantly improved signs of photodamage, including wrinkles, laxity and skin tone. Both products were generally well-tolerated and 93% reported overall satisfaction with both products. Our four panelists were in agreement that most skincare products still need additional study and more rigorous clinical trials. ���Whether we���re talking about growth factors or antioxidants, we need clinical data on all of these elements and how they activate different rebuilding pathways,��� Mehta says. ���How each is stabilized and delivered is equally as important. Lots of things need to be proven. For example, there are lots of retinoids in a variety of skincare products but retinoids cause irritation to the skin and are notoriously unstable. They need to be used in formulations that stabilize the retinoids and help reduce irritation.��� ME Linda Lewis is a contributing editor of MedEsthetics.

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - MAR-APR 2013